Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis

Clinical and Experimental Immunology

Volumn 176, Issue 2, 2014, Pages 207-221

  Wang, Y Z ^a,c   Tian, F F ^a   Yan, M ^b   Zhang, J M ^a   Liu, Q ^a   Lu, J Y ^a   Zhou, W B ^a   Yang, H ^a   Li, J ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

^c JINING MEDICAL UNIVERSITY   (China)

Author keywords

Experimental autoimmune myasthenia gravis; Immunomodulation; MiRNA; RNA interference

Indexed keywords

ANTIBODY CONJUGATE; B CELL ACTIVATING FACTOR RECEPTOR; B7 ANTIGEN; CD20 ANTIBODY; CD20 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY ANTAGOMIR155; CD40 ANTIGEN; CD86 ANTIGEN; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINERGIC RECEPTOR; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOLOGIC AGENT; MICRORNA 155; PROTEIN BCL 2; PROTEIN BCL XL; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEMORY CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TORPEDO; UPREGULATION;

EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; IMMUNOMODULATION; MIRNA; RNA INTERFERENCE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIGENS, CD20; AUTOANTIBODIES; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL NUCLEUS; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; MICRORNAS; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; NF-KAPPA B; RECEPTORS, CHOLINERGIC; RECEPTORS, INTERLEUKIN-4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE-CHAIN ANTIBODIES; TORPEDO;

EID: 84897931769     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12265     Document Type: Article

References (67)

1. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26:1054-1059.
2. Hoch W, McConville J, Helms S etal. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7:365-368.
3. Berman PW, Patrick J. Experimental myasthenia gravis. A murine system. J Exp Med 1980; 151:204-223.
4. Standifer NE, Kraig E, Infante AJ. A hierarchy of T cell receptor motifs determines responsiveness to the immunodominant epitope in experimental autoimmune myasthenia gravis. J Neuroimmunol 2003; 145:68-76.
5. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 2011; 11:163-175.
6. Ha TY. The role of MicroRNAs in regulatory T cells and in the immune response. Immune Netw 2011; 11:11-41.
7. Thai TH, Calado DP, Casola S etal. Regulation of the germinal center response by microRNA-155. Science 2007; 316:604-608.
8. Rodriguez A, Vigorito E, Clare S etal. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316:608-611.
9. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103:12481-12486.
10. van den Berg A, Kroesen BJ, Kooistra K etal. High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Genes Chromosomes Cancer 2003; 37:20-28.
11. Haasch D, Chen YW, Reilly RM etal. T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol 2002; 217:78-86.
12. Vigorito E, Perks KL, Abreu-Goodger C etal. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007; 27:847-859.
13. Krutzfeldt J, Rajewsky N, Braich R etal. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438:685-689.
14. Peterson E, Owens SM, Henry RL. Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse. AAPS J 2006; 8:E383-390.
15. Kumar P, Ban HS, Kim SS etal. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008; 134:577-586.
16. Kaminski MS, Zasadny KR, Francis IR etal. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14:1974-1981.
17. Maloney DG, Liles TM, Czerwinski DK etal. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84:2457-2466.
18. Haisma HJ, Sernee MF, Hooijberg E etal. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Blood 1998; 92:184-190.
19. Jaretzki A 3rd, Barohn RJ, Ernstoff RM etal. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000; 55:16-23.
20. Sharshar T, Chevret S, Mazighi M etal. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J Neurol 2000; 247:286-290.
21. Lindstrom J, Einarson B, Tzartos S. Production and assay of antibodies to acetylcholine receptors. Methods Enzymol 1981; 74: 432-460.
22. Wu B, Goluszko E, Huda R, Tuzun E, Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Curr Protoc Immunol 2011; Chapter 15:Unit 15 23.
23. Reff ME, Carner K, Chambers KS etal. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-445.
24. Shan D, Press OW, Tsu TT, Hayden MS, Ledbetter JA. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. J Immunol 1999; 162:6589-6595.
25. Hendricks J, Visser A, Dammers PM etal. Class-switched marginal zone B cells in spleen have relatively low numbers of somatic mutations. Mol Immunol 2011; 48:874-882.
26. Moore PA, Belvedere O, Orr A etal. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285:260-263.
27. Scuderi F, Alboini PE, Bartoccioni E, Evoli A. BAFF serum levels in myasthenia gravis: effects of therapy. J Neurol 2011; 258:2284-2285.
28. Ragheb S, Lisak R, Lewis R etal. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol 2008; 65:1358-1362.
29. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27:693-733.
30. Sun SC, Ley SC. New insights into NF-kappaB regulation and function. Trends Immunol 2008; 29:469-478.
31. Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res 2011; 21:71-85.
32. Jurgensmeier JM, Xie Z, Deveraux Q etal. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998; 95:4997-5002.
33. Do RK, Hatada E, Lee H etal. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000; 192:953-964.
34. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005; 202:1363-1374.
35. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006; 18:263-275.
36. DeKoter RP, Walsh JC, Singh H. PU.1 regulates both cytokine-dependent proliferation and differentiation of granulocyte/macrophage progenitors. EMBO J 1998; 17:4456-4468.
37. Martinez-Nunez RT, Louafi F, Friedmann PS, Sanchez-Elsner T. MicroRNA-155 modulates the pathogen binding ability of dendritic cells (DCs) by down-regulation of DC-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN). J Biol Chem 2009; 284:16334-16342.
38. Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature 1994; 367:425-428.
39. Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002; 277:7766-7775.
40. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol 2002; 2:323-335.
41. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010; 10:111-122.
42. Lu LF, Thai TH, Calado DP etal. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009; 30:80-91.
43. Yin Q, Wang X, McBride J, Fewell C, Flemington E. B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. J Biol Chem 2008; 283:2654-2662.
44. Kurowska-Stolarska M, Alivernini S, Ballantine LE etal. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA 2011; 108:11193-11198.
45. O'Connell RM, Kahn D, Gibson WS etal. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010; 33:607-619.
46. Gironella M, Seux M, Xie MJ etal. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007; 104:16170-16175.
47. Marton S, Garcia MR, Robello C etal. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 2008; 22:330-338.
48. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140-174.
49. Li A, Ojogho O, Escher A. Saving death: apoptosis for intervention in transplantation and autoimmunity. Clin Dev Immunol 2006; 13:273-282.
50. Kansas GS, Tedder TF. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J Immunol 1991; 147:4094-4102.
51. Kim YH, Choi BH, Cheon HG, Do MS. B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation. Exp Mol Med 2009; 41:208-216.
52. Otipoby KL, Sasaki Y, Schmidt-Supprian M etal. BAFF activates Akt and Erk through BAFF-R in an IKK1-dependent manner in primary mouse B cells. Proc Natl Acad Sci USA 2008; 105:12435-12438.
53. Li PP, Liu DD, Liu YJ etal. BAFF/BAFF-R involved in antibodies production of rats with collagen-induced arthritis via PI3K-Akt-mTOR signaling and the regulation of paeoniflorin. J Ethnopharmacol 2012; 141:290-300.
54. Fasanaro P, Greco S, Ivan M, Capogrossi MC, Martelli F. microRNA: emerging therapeutic targets in acute ischemic diseases. Pharmacol Ther 2010; 125:92-104.
55. Hupalowska A, Pyrzynska B, Miaczynska M. APPL1 regulates basal NF-kappaB activity by stabilizing NIK. J Cell Sci 2012; 125:4090-4102.
56. Im SH, Barchan D, Maiti PK, Fuchs S, Souroujon MC. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J Immunol 2001; 166:6893-6898.
57. Carlring J, Altaher HM, Clark S etal. CD154-CD40 interactions in the control of murine B cell hematopoiesis. J Leukoc Biol 2011; 89:697-706.
58. McAdam AJ, Farkash EA, Gewurz BE, Sharpe AH. B7 costimulation is critical for antibody class switching and CD8(+) cytotoxic T-lymphocyte generation in the host response to vesicular stomatitis virus. J Virol 2000; 74:203-208.
59. Ziller C, Stoeckel F, Boon L, Haegel-Kronenberger H. Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector. Gene Ther 2002; 9:537-546.
60. Schneider P, MacKay F, Steiner V etal. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189:1747-1756.
61. MacPherson G, Kushnir N, Wykes M. Dendritic cells, B cells and the regulation of antibody synthesis. Immunol Rev 1999; 172:325-334.
62. Balazs M, Martin F, Zhou T, Kearney J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 2002; 17:341-352.
63. Attanavanich K, Kearney JF. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J Immunol 2004; 172:803-811.
64. Oliver AM, Martin F, Kearney JF. IgMhighCD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. J Immunol 1999; 162:7198-7207.
65. Gross JA, Dillon SR, Mudri S etal. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15:289-302.
66. Schiemann B, Gommerman JL, Vora K etal. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293:2111-2114.
67. Sims GP, Shiono H, Willcox N, Stott DI. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol 2001; 167:1935-1944.